Replies to post #188897 on Cytodyn Inc (CYDY)

[justdafactss]

Who said (clinical proof) almost no drug was left in the system at 21 and 28 days?

And this---

On October 20, 2020, following review and recommendation by the Data Safety Monitoring Committee (DSMC) of data from 195 patients, the Company continued the trial without modification to achieve the primary endpoint. The DSMC also requested a second review of the data after 75% (or 293) of the patients were enrolled and completed a 42-day post-enrollment period. The Company has concluded it will be far more time efficient to forego the second interim analysis and to analyze the data on 390 patients and to provide final data to the U.S. Food and Drug Administration, Health Canada, U.K.’s MHRA, and Philippines FDA, as soon as it is available.
https://finance.yahoo.com/news/cytodyn-completes-enrollment-phase-3-210100792.html

Bottom line...how did CYDY finally wash up by providing final data to the U.S. Food and Drug Administration, Health Canada, U.K.’s MHRA, and Philippines FDA as it was available?

[Leronlimab4DaWin]

Ask yourself this: if this drug were so good why would they be forced to induce and sell shares at a 50%+ discount to current prices, with immediately liquidity? Why wouldn’t any of the hundred of well backed institutions write them an equity check to buyout Fife’s convert and give them adequate working capital?

Ok now try answering without saying “BP trying to hold Loserlimab down”